Ramesh Ramachandran is recorded as Chief Accounting Officer and CFO at Ocugen, Inc. (OCGN) since November 14, 2024. Ocugen, Inc. reported in an 8-K filed June 3, 2026 that Ramesh Ramachandran resigned as Chief Accounting Officer, effective May 29, 2026. Ocugen, Inc. reported in an 8-K filed November 15, 2024 that Ramesh Ramachandran was appointed principal accounting officer, effective November 14, 2024. Ocugen, Inc. reported in an 8-K filed November 15, 2024 that Ramesh Ramachandran was appointed principal financial officer, effective November 14, 2024. The proxy statement of Ocugen, Inc. reports total compensation of $1,192,089 for Ramesh Ramachandran in fiscal 2025, including a base salary of $360,500. Ramesh Ramachandran has spoken on 5 earnings calls across 1 company, most recently for Ocugen, Inc. on November 5, 2025. Ocugen, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ocugen, Inc. includes Shankar Musunuri (CEO), Quan Anh Vu (CFO), Rita Johnson Green (CFO) and 5 others.
“Effective May 29, 2026, Ramesh Ramachandran, CPA, MBA, CMA, resigned as the Chief Accounting Officer of Ocugen, Inc. (the "Company").”
“On November 14, 2024 (the "Effective Date"), the Board of Directors of Ocugen, Inc. (the "Company") appointed Ramesh Ramachandran to serve as the Company's principal financial officer and principal accounting officer, effective as of the Effective Date”
Ocugen, Inc. Form 8-K, filed November 15, 2024
· Read the filing
Ramesh Ramachandran on recent calls
“The company's cash, cash equivalents and restricted cash totaled $32.9 million as of September 30, 2025, compared to $58.8 million as of December 31, 2024.”
“The company's cash, cash equivalents, and restricted cash totaled $27.3 million as of June 30, 2025, compared to $58.8 million as of December 31, 2024. The company had 292.2 million shares of common stock outstanding as of June 30, 2025.”
“Our research and development expenses for the quarter ended March 31, 2025, were $9.5 million compared to $6.8 million for the first quarter of 2024. General and administrative expenses for the quarter ended March 31, 2025, were $6.5 million compared to $6.4 million during the same period in 2024.”
“I will now provide an overview of the key financial results for the fourth quarter and full year of 2024. Our research and development expenses for the quarter ended December 31, 2024, were $8.3 million compared to $7.8 million for the fourth quarter of 2023.”
